Human colorectal carcinomas frequently express elevated levels of c-myc mRNA in the absence of a gross genetic change at the c-myc locus. To test the hypothesis that these tumors are defective in a gene function necessary for the regulation of c-myc expression, we fused an osteosarcoma cell line that exhibits normal c-myc regulation with two colon carcinoma cell lines that express deregulated levels of c-myc mRNA. The levels of c-myc transcripts in all of the hybrid clones examined were normal and were induced normally by a mitogenic stimulus. Since rates of c-myc mRNA turnover in the colon carcinoma cells were found to be comparable to those in normal cells, increased message stability cannot account for the increased steady-state levels of transcripts. Our findings suggest that loss of function of a trans-acting regulator is responsible for the deregulation of c-myc expression in a major fraction of colorectal carcinomas.
normal cells, increased message stability cannot account for the increased steady-state levels of transcripts. Our findings suggest that loss of function of a trans-acting regulator is responsible for the deregulation of c-myc expression in a major fraction of colorectal carcinomas. Analysis of restriction fragment length polymorphisms in tumor/normal tissue pairs from patients with primary colorectal lesions indicated that deregulation of c-myc expression in the tumors is correlated with frequent loss of alleles of syntenic markers on chromosome 5q; allele loss on 5q could be detected in 9 of 19 tumors expressing deregulated levels of c-myc mRNA, but not in any of 8 tumors expressing normal levels of c-myc RNA. Chromosome 5q is the region known to contain the gene for familial adenomatous polyposis, an inherited predisposition to colon cancer. These findings, together with the earlier finding that the colonic distribution of tumors exhibiting deregulated c-myc expression is similar to that reported for familial polyposis, provide evidence that loss of function of the familial adenomatous polyposis gene is involved in a subset of colorectal cancers in which c-myc expression is deregulated.
The deregulated expression of the c-myc oncogene has been recognized as an initiating or contributing factor in the development of chicken bursal lymphomas (1), murine plasmacytomas (2) , and human Burkitt lymphomas (3) . In each case, a cis-acting genetic change has been identified that affects the transcriptional activity of the c-myc locus; these changes are the result of insertional mutagenesis by viruses (chicken) or reciprocal chromosome translocations involving the immunoglobulin loci (mouse and man). Increased expression of the c-myc locus also occurs in some human lung (4) and breast (5) carcinomas as a result of gene amplification that appears to occur during tumor progression.
A majority of human colorectal carcinomas also have significantly elevated levels of c-myc mRNA and protein (6) (7) (8) (9) (10) (11) (12) (13) . Seventy percent of the primary adenocarcinomas of the colon examined by Erisman et al. had levels of c-myc mRNA that were 5-to 40-fold higher than the levels observed in normal colonic mucosa (6) , and the levels of the encoded protein (p64c-mYc) observed in tumor-derived cell lines were correspondingly high (8) . Gross change at the c-myc locus is rarely seen in these tumors and is limited, in such cases, to moderate levels of gene amplification (6, 8, 11) . As a result, it was suggested (6) that colorectal carcinomas have a defect in another gene that normally acts in trans to regulate expression of the c-myc locus. This hypothesis predicts that c-myc regulation might be restored in hybrids between colon carcinoma cells that express deregulated c-myc and cells that regulate the gene normally. We have tested this prediction in the present work.
We have also explored the possibility of a relationship between c-myc regulation and the gene for familial adenomatous polyposis (FAP). FAP is characterized by the development of large numbers of polyps during the first 20-30 years of life and the subsequent appearance of frank colorectal adenocarcinoma as early as age 40. The "two-hit" mechanism, originally proposed by Knudson (14) to explain the sporadic and inherited forms of retinoblastoma (RB), can be applied to oncogenesis involving the FAP locus. That is, ifthe FAP gene acts phenotypically as a suppressor of neoplastic disease (15) , or "anti-oncogene" (16) , the inheritance of a defect in one copy would result in a predisposition to cancer (17) , since loss or mutation of the other allele would lead to oncogenesis. The possibility that this gene is involved in a subset of tumors that express deregulated c-myc arose from the earlier finding that, like primary tumors in individuals with FAP, a disproportionate number of colorectal tumors with elevated levels of c-myc mRNA arise in the left (descending) colon (7, 9) .
We have therefore sought further independent evidence for a correlation between loss of FAP gene function and c-myc deregulation. Linkage analyses in polyposis probands (18, 19) have localized the FAP locus (APC, for adenomatous polyposis coli) to chromosome 5 near bands 5q21-q22. In addition, allele loss on 5q has also been documented in >20% of sporadic (nonfamilial) colorectal carcinomas (20) . In the experiments reported here, we tested whether allele loss on chromosome 5q is correlated with c-myc gene deregulation. tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. prepared by electroporation (21, 22) of linearized pSV2neo plasmid DNA (23) . Polyethylene glycol-mediated cell fusions (24) were carried out using trypsin-treated, late-logarithmicphase cells that were incubated in suspension with phytohemagglutinin (40 ,ug/ml) for 30 min at 370C prior to fusion (25) or by direct polyethylene glycol-mediated fusion of monolayer cocultures. Selection with hypoxanthine/aminopterin/ thymidine (HAT) medium containing G418 sulfate (400-800 Ag/ml) was imposed and continuously maintained beginning 24-36 hr after fusion. Individual clones were isolated and expanded for molecular analyses. Approximate population doubling times were determined from cell counts during logarithmic growth.
Measurement of mRNA Half-life. Early-log-phase cell cultures were treated with actinomycin D (5 ug/ml) 36-48 hr after their last feeding. Total cellular RNA was recovered from treated cells at specific times after addition of the drug, and dot blots were prepared as described below. The relative abundance of c-myc mRNA was determined by scanning densitometry of dot blots, and the rate of turnover was estimated by regression analysis of the relative densities obtained.
RNA and DNA Analysis. Total cellular RNA was recovered from late-log-phase cell cultures and primary tumor tissue lysed in guanidinium isothiocyanate and fractionated on cesium chloride cushions as described (8) . Dot blot and Northern blot (26) analyses were carried out with glyoxalated total cellular RNA that was hybridized with a 32P-labeled probe for exon 3 ofthe human c-myc gene (6, 8) . A 32P-labeled f32-microglobulin probe (27) was used as a control for RNA integrity (6) . Methylene blue staining of rRNA and RNA size standards (Bethesda Research Laboratories) on Northern blots was carried out by published methods (28) . Total cellular DNA was recovered from primary tumor tissue as described (6) . Southern blot (29) analysis of Hinfl-digested tumor DNAs was carried out exactly as detailed previously (6) with a 32P-labeled human minisatellite probe called AMS8 (D5S43) (30) , which hybridizes to sequences on chromosome 5 (5q34-qter). The relative densities of the bands representing polymorphic alleles observed in Southern blots hybridized to this probe were determined by a computerized scanning densitometer. Loss of heterozygosity in informative cases was defined as .50% loss of a given band intensity relative to that of the companion allele when normalized to the ratio of band intensities in the matched normal control.
subsequently evaluated for steady-state levels of c-myc RNA and for the ability to modulate c-myc expression in response to a mitogenic stimulus. Drug-insensitive revertants of the parental lines have not been observed; thus, it seems likely that the stringently selected clones are colon carcinomaosteosarcoma hybrids. The possibility of selective loss of a cis-activated allele(s) from the colon donor could not be addressed directly, since sufficient restriction fragment length polymorphisms appropriate for this analysis were not available. However, the genetic stability of intraspecific hybrids in general and the fact that identical results were obtained for c-myc expression in 12 clones from two different fusions make the fortuitous loss of c-myc alleles from the colon parent seem an unlikely explanation for the results. Moreover, the chromosomal complements of these two hybrids were found to approximate the sum of the parental karyotypes (data not shown).
Levels of c-myc Gene Expression in the Hybrids. To determine steady-state levels of c-myc mRNA for the parental cell lines and their hybrids, dot blots of total cellular RNA were hybridized to an exon 3 probe from the human c-myc gene ( 
RESULTS
Characterization of Colon Carcinoma-Osteosarcoma Cell Hybrids. The human colorectal adenocarcinoma cell lines SW1116 and DLD-1 are characteristic of many primary colorectal tumors (6, 11, 12) and tumor-derived cell lines (8) in that (i) the steady-state levels of c-myc mRNA are 8-to 10-fold higher than those observed in tissue and cells from normal colonic mucosa and (ii) these levels are not significantly modulated in response to mitogenic stimuli. Neither cell line exhibits rearrangement or amplification of the c-myc locus. To determine whether the defect in c-myc regulation can be complemented in trans, we fused each of these cell lines with a human cell line that regulates the gene normally. The fusion partner used was a murine sarcoma virustransformed, thymidine kinase-deficient, human osteosarcoma cell line (GM5887) resistant to the cytotoxic effects of G418. The GM5887 (HATS, G418') parent exhibits the lowlevel, steady-state expression of the c-myc gene typically observed in asynchronously growing populations of normal cells that have not been treated with mitogens (31) . Fusion of this cell line with either of the colorectal cell lines (HATr, G418s), followed by stringent selection in drug-containing medium, provided hybrid clones (HATr, G4189 that were Northern blots hybridized with a f82-microglobulin probe (27 (27) showed that the levels of 82-microglobulin mRNA in GM5887, SW1116, and two of their hybrids were similar (Fig. ic) , indicating that the observed reduction in c-myc mRNA in the hybrids was not the result of a generalized diminution of mRNA levels. Expression of the 82-microglobulin gene in the DLD-1 cell line was reproducibly lower than in the other parental lines and hybrids examined. The integrity of RNA in each sample was confirmed by methylene blue staining of rRNA (Fig. ld) . The (8) .
by the fusion of GM5887 and SW1116, expressed c-myc mRNA at basal levels in late-log-phase cultures ( Fig. 1) and exhibited a transient increase in c-myc expression in response to mitogenic stimulus, similar to that observed with the GM5887 parent (Fig. 2) We used a locus-specific, minisatellite probe (AMS8) that maps distal (5q34-qter) to the FAP gene (30) to assay for allele loss on 5q in a panel of colorectal tumors; DNA samples from tumor/normal tissue pairs were available for this analysis. Levels ofc-myc mRNA in each sample were determined as previously reported (6, 7, 9) . Of the 39 cases examined, 26 (67%) had levels of c-myc mRNA .5-fold higher than in normal mucosa from the same patient; 13 (33%) had levels of mRNA -2-fold higher than corresponding controls.
Tumor and normal DNAs from these 39 cases were digested with the restriction endonuclease Hinfl, and Southern blots of these digests were hybridized to 32P-labeled AMS8 probe. The region detected by this probe is extremely polymorphic; two alleles can be distinguished in -90% of individuals due to differences in location of restriction enzyme sites (20) . Twenty-seven of the 39 cases we examined (69%) were informative, i.e., exhibited two distinguishable alleles in digests of DNA from normal tissue. The difference between 69% and 90% could be statistical or could reflect real population differences (United States versus United Kingdom). Loss of heterozygosity in the tumors from these 27 cases was judged on the basis of allele loss exceeding 50% in the tumor sample when normalized to the corresponding normal control. Computerized scanning densitometry was used for the quantitation (data not shown). Although allele loss is presumed to be complete in the tumor cells, contamination of the tumor sample with normal cells causes a diminution rather than absolute loss of signal for one allele, as reported by others (20) .
Tumors from eight of the informative cases had levels of c-myc mRNA that were not elevated (<2-fold higher than normal mucosa). None of these tumors exhibited loss of heterozygosity by the above criterion (Fig. 3, top row) . The remaining 19 tumors from informative cases had levels of Results from Southern blot analysis of 27 informative cases in which DNA was digested with Hinfl and probed with radiolabeled AMS8 DNA are shown. The level ofc-myc mRNA in tumor tissue relative to normal mucosa was graded as follows: -, no increase; +, <2-fold increase; + +, -5-fold increase; + + +, n0-fold increase; + ++ +, >10-fold increase (6, 7, 9) . N, normal colonic mucosa; C, primary adenocarcinoma. Alleles that have undergone loss exceeding 50%o normalized to controls are indicated by arrowheads. CL and CR, carcinoma ofthe left and right sides of the colon, respectively. CD and Cp, carcinomas of the distal (left) and proximal (right) colon, respectively. c-myc mRNA that were elevated (25-fold higher than normal mucosa). Ten of these tumors exhibited no loss of heterozygosity (Fig. 3, middle row) ; however, 9 of the 19 tumors with high c-myc mRNA (47%) showed loss of one allele (Fig. 3,  bottom row) . Thus, all 9 tumors exhibiting allele loss of Sq expressed elevated levels of c-myc mRNA; no tumor expressing normal levels of c-myc mRNA showed allele loss.
Two FAP cases were also available for examination (Fig.  3) . One of these (FAP 1, middle row) exhibited no loss of heterozygosity in primary tumor tissue resected from either the left or right colon. The tumors exhibited a 5-to 10-fold increase in c-myc mRNA. The second (FAP 2, bottom row) showed allele loss in one of two primary tumors recovered from the same resection of large bowel; both tumors exhibited a 3-to 4-fold elevation of c-myc gene expression.
DISCUSSION
Previous work showed that >80% of primary carcinomas of the left colon exhibit constitutively high levels of c-myc expression (6, 7, 9) . We propose that this defect in regulation has an important oncogenic role in this tissue, as is already known to be the case in cancers of the immune system (1) (2) (3) . Since the deregulation is not accompanied by amplification or rearrangement of the c-myc locus or by a significant change in stability of the message, we have suggested the involvement of a trans-acting regulator of c-myc transcription. In support of this view, we now show that the defect can be corrected by fusion with a cell in which c-myc expression is regulated. These findings provide evidence that lesions in trans-acting regulators can result in deregulation of c-myc. The identification of these trans-acting genes and elucidation of their mechanisms of action are subjects of major interest.
The genetic predisposition to colorectal carcinoma (18, 19, 35) , and the development of a major fraction of nonfamilial colorectal carcinomas (20) (36) , RB (37) (38) (39) , and other neoplastic diseases (40) . The evidence for involvement ofthe FAP locus in sporadic colon cancer comes from the observation that >23% of colorectal carcinoma samples show allele loss on chromosome Sq (20) , the chromosome to which the FAP gene locus maps. The loss represents a conversion to homozygosity for alleles on 5q, including the FAP locus. Presumably, the function of both copies of the FAP gene must be lost in order for a tumor to develop. It is thus assumed that one allele suffers a small local lesion (point mutation or small deletion) and that the second allele is lost either through a local lesion or by a more global event, such as large deletion or a loss of the entire chromosome (often followed by duplication of the mutant chromosome), or by somatic recombination leading to homozygosity of the defect. The global events result in loss not only of the normal FAP allele but also of heterozygosity for all the genes distal to it, including the locus to which the minisatellite probe used in this study hybridizes. That one of four tumors from FAP patients showed allele loss on 5q is consistent with the idea that loss of FAP gene function can occur both by a gross mechanism and by a local lesion.
It is significant that 9 (47%) of the 19 tumors with elevated c-myc expression showed loss of heterozygosity of Sq markers, whereas none ofthe 8 tumors with normal levels ofc-myc expression showed allele loss. or loss of both copies of a critical anti-oncogene located on chromosome 5q. Our colon tumor data, in conjunction with the observation that the four tumors from FAP patients we analyzed expressed elevated levels of c-myc mRNA, lend support to this proposal. It is possible that there is a causal relationship between loss of FAP gene function and c-myc deregulation. The FAP gene product may act to regulate c-myc either directly or through another gene or gene product. Alternatively, there may not be a causal relationship between the two, but both may be required for oncogenesis in a subset of colon cancers. The possibility that oncogenes and anti-oncogenes might interact has been a topic of considerable interest and speculation. A model has recently been proposed (41) in which the interaction occurs entirely at the protein level-i.e., a protein encoded by an oncogene (the adenovirus ElA gene) binds to a protein encoded by an anti-oncogene (the RB gene). The RB gene codes for a 110-kDa nuclear phosphoprotein (42) whose function appears to be necessary for the normal control of cell proliferation. It has been suggested that binding of the ElA protein to the RB gene product interferes with its normal function and therefore, like loss of the RB gene, leads to uncontrolled growth and tumor formation (41) . We suggest that the FAP gene product, like the RB gene product, is necessary for control of cell proliferation and, further, that loss of FAP gene function is correlated with deregulated c-myc expression. The mechanism by which the RB product controls cell proliferation is not known. It does, however, appear to be a DNA-binding protein (42) , and may therefore function to regulate directly a gene, like c-myc, whose product is necessary for cell division.
There is a subset of colon carcinomas in which c-myc expression is not deregulated. In addition, not all hereditary colon cancer involves the FAP locus (43); therefore, this locus is probably not involved in all sporadic colon cancer. We surmise that the tumors that express regulated c-myc represent a distinct subgroup that involves somatic mutation at a site other than the FAP locus-i.e., at the site of an anti-oncogene other than FAP, possibly the hereditary nonpolyposis gene.
In conclusion, our data provide evidence that loss of function of a trans-acting regulator of c-myc transcription is a mechanism of c-myc deregulation in human colon carcinoma. In addition, there is a correlation between this deregulation and loss of heterozygosity on chromosome 5q, the chromosomal location of the FAP gene. Whether there is a causal relationship between the FAP gene product and trans regulation of c-myc remains to be determined.
